![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Health Discovery Corporation (CE) | USOTC:HDVY | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 00:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October 19, 2022
Health Discovery Corporation
(Exact name of registrant as specified in charter)
GA | 333-62216 | 74-3002154 | ||
(State of incorporation) | (Commission File Number) |
(IRS Employer Identification No.) |
2002 SUMMIT BLVD, SUITE 300 | ||
ATLANTA, GA | 30319 | |
(Address of principal executive offices) | (Zip Code) |
(404) 566-4865
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act.
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
☐ Pre-commencement communications pursuant to Rule 14d–2(b) under the Exchange Act.
☐ Pre-commencement communications pursuant to Rule 13e–4(c) under the Exchange Act.
Securities registered pursuant to Section 12(g) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, no par value | HDVY | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 | Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. |
On October 19, 2022, Jim Murphy notified George H. McGovern, III, Chairman and Chief Executive Officer of Health Discovery Corporation (the “Company”) in an email that he intended to resign from his position as a director of the Company. Mr. Murphy stated that his resignation was due entirely to personal reasons. Mr. Murphy further stated that he had no disagreements with the Company or any of its directors, officers or other personnel.
Item 9.01 | Financial Statements and Exhibits |
(d) | Exhibits |
99.1 | Jim Murphy’s Resignation Email | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
HEALTH DISCOVERY CORPORATION | |||
|
|
||
Dated: October 26, 2022 | By: | /s/ George H. McGovern, III | |
George H. McGovern, III Chairman & Chief Executive Officer |
2 |
1 Year Health Discovery (CE) Chart |
1 Month Health Discovery (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions